Early T cell precursor acute lymphoblastic leukemia is a relatively new,
high risk subgroup of acute lymphoblastic leukemia characterized by
unique immune-phenotype and disease biology. ETP ALL cells share
similarities with hematopoietic stem cells and myeloid progenitor cells.
These patients have lower rates of complete remission overall survival.
Venetoclax is an orally bioavailable BCL 2 inhibitor. We report the
treatment outcomes of 2 patients with ETP ALL who achieved MRD negative
remission with short course of venetoclax.